Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Recent Quotes

View More
Symbol Price Change (%)
AMZN  206.78
+1.51 (0.74%)
AAPL  273.13
+6.95 (2.61%)
AMD  209.75
+13.15 (6.69%)
BAC  49.95
-1.12 (-2.18%)
GOOG  307.03
-4.66 (-1.50%)
META  635.10
-2.15 (-0.34%)
MSFT  387.70
+3.23 (0.84%)
NVDA  190.86
-0.69 (-0.36%)
ORCL  145.88
+4.57 (3.23%)
TSLA  402.88
+3.05 (0.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.